Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
48 Glaucoma Trials near Long Beach, CA
Power is an online platform that helps thousands of Glaucoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerT4090 vs Rhopressa for Glaucoma
Torrance, California
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
126 Participants Needed
AGN-193408 SR for Glaucoma
Torrance, California
This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
Must Not Be Taking:Corticosteroids
96 Participants Needed
iStent Inject for Glaucoma
Torrance, California
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Key Eligibility Criteria
Disqualifiers:Angle Closure Glaucoma, Others
358 Participants Needed
Streamline Surgical System vs iStent for Open-Angle Glaucoma
Torrance, California
A study of the Streamline Surgical System versus competitor
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Key Eligibility Criteria
Disqualifiers:Other Glaucoma Types, Ocular Hypertension
150 Participants Needed
NCX 470 for Glaucoma
Huntington Beach, California
This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Narrow Angles, Ocular Disease, Surgery, Others
696 Participants Needed
Bimatoprost SR for Glaucoma
Huntington Beach, California
This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Concurrent Study, Previous Bimatoprost SR
515 Participants Needed
Travoprost Implant for Glaucoma
Torrance, California
This trial tests a small device that releases medication inside the eye to help patients with high eye pressure due to glaucoma or ocular hypertension. The medication helps fluid drain from the eye, reducing pressure and preventing vision problems.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
105 Participants Needed
Long-term Safety and Efficacy of Bimatoprost SR for Glaucoma
Torrance, California
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Other Drug Studies, Others
Must Be Taking:Bimatoprost SR
455 Participants Needed
BL1107 Eye Drops for Glaucoma
Newport Beach, California
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Orthostatic Hypotension, Active Ocular Disease, Others
228 Participants Needed
Hydrus Microstent for Glaucoma
Orange, California
This trial is evaluating the placement and effects of a tiny device called the Hydrus Microstent in patients having cataract surgery. The device helps drain fluid from the eye to reduce pressure. The study will monitor patients over time to see how well the device works and if there are any issues. The Hydrus Microstent is designed to increase fluid drainage from the eye and lower eye pressure.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:45+
Key Eligibility Criteria
Disqualifiers:Closed Angle Glaucoma, Secondary Glaucoma, Others
Must Be Taking:Topical Hypotensives
545 Participants Needed
AMDX-2011P for Glaucoma
Newport Beach, California
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:22+
Key Eligibility Criteria
Disqualifiers:Not Listed
50 Participants Needed
Reformulated PG324 for Glaucoma
Newport Beach, California
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Intraocular Pressure > 36 MmHg, Others
Must Be Taking:Ocular Hypotensives
470 Participants Needed
PA5108 Ocular Implants for Glaucoma
Newport Beach, California
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Advanced Glaucoma, Uncontrolled Conditions, Others
75 Participants Needed
Bimatoprost Solutions for Glaucoma
Newport Beach, California
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Hepatic Impairment, Uncontrolled Systemic Disease, Others
Must Be Taking:Parasympathomimetics, Carbonic Anhydrase Inhibitors
240 Participants Needed
Eye Drops for Open-Angle Glaucoma
Garden Grove, California
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Glaucoma, Glaucoma Surgery, Others
Must Not Be Taking:Ocular Hypotensives
426 Participants Needed
Gel Stent for Glaucoma
Culver City, California
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed.
XEN63 is an investigational device for the treatment of intraocular pressure (IOP) in patients with glaucoma when both medical and conventional surgical treatments have failed (for US approval) and when medical treatments have failed (for outside US \[OUS\] approval). Participants will be placed in one of two groups called study arms. One group will receive the XEN63 gel stent ab interno (inside the eye) and the other group will receive the XEN63 gel stent ab externo (outside the eye). Approximately 130 participants aged 45 years or older with glaucoma will be enrolled in this study at approximately 32 sites in the United States.
Participants will receive XEN63 implanted using either the ab interno approach or the ab externo approach on Day 1 and will be followed for 12 months.
Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Key Eligibility Criteria
Disqualifiers:Angle-closure Glaucoma, Secondary Open-angle Glaucoma, Others
Must Be Taking:IOP-lowering Medications
130 Participants Needed
MINIject™ Implant for Glaucoma
Beverly Hills, California
This trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:46+
Key Eligibility Criteria
Disqualifiers:Angle Closure Glaucoma, Degenerative Visual Disorders, Others
975 Participants Needed
Selective Laser Trabeculoplasty for Glaucoma
Pasadena, California
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Advanced POAG, Other Glaucoma, Others
Must Not Be Taking:Topical IOP-lowering
790 Participants Needed
T4090 Eye Drops for Glaucoma and Ocular Hypertension
Glendale, California
This trial is testing a new treatment called T4090 to see if it is safe for people. The study includes a wide range of participants to ensure the treatment does not cause harm.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
120 Participants Needed
XEN45 Gel Stent for Open-Angle Glaucoma
Ventura, California
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed.
XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States.
All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months.
Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Key Eligibility Criteria
Disqualifiers:Unhealthy Conjunctiva, Excessive Bleeding, Others
65 Participants Needed
Why Other Patients Applied
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
Excimer Laser Trabeculostomy for Glaucoma
Las Vegas, Nevada
This trial evaluates the safety and effectiveness of the ELIOS System, a procedure to lower eye pressure, in adults with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:45+
Key Eligibility Criteria
Disqualifiers:Closed-angle Glaucoma, Corneal Surgery, Others
Must Not Be Taking:Corticosteroids
318 Participants Needed
Rocklatan for Glaucoma
Las Vegas, Nevada
The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:40+
Key Eligibility Criteria
Disqualifiers:Severe Glaucoma, Retinal Diseases, Others
Must Not Be Taking:Steroids
68 Participants Needed
Nicotinamide + Pyruvate for Open-Angle Glaucoma
Palo Alto, California
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.
A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:35 - 85
Key Eligibility Criteria
Disqualifiers:Cataract, Dementia, Neurological Disease, Others
Must Be Taking:Glaucoma Medications
250 Participants Needed
NT-501 Cell Therapy for Glaucoma
Palo Alto, California
This trial tests tiny devices that release a protective protein into the eyes of patients with glaucoma-related vision problems. The protein helps protect nerve cells, potentially preventing further vision loss and improving sight.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Retinal Disease, Cataracts, Diabetes, Others
Must Not Be Taking:Acyclovir, Steroids, Immunosuppressants, Chemotherapy
30 Participants Needed
NT-501 ECT Implant for Glaucoma
Palo Alto, California
This trial tests a new eye implant called NT-501 for people with glaucoma. The implant releases medicine directly into the eye to help protect it from damage. It aims to help those who may not respond well to usual treatments. An earlier version of this implant has been used to help manage glaucoma in patients who did not benefit from other treatments.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Retinal Disease, Diabetic Retinopathy, Pregnancy, Others
Must Not Be Taking:Acyclovir, Immunosuppressives, Chemotherapy, Others
54 Participants Needed
Topical Insulin for Glaucoma
Palo Alto, California
This trial is testing the safety of applying a special form of insulin directly to the eye in patients with optic nerve damage from conditions like glaucoma. The insulin may help heal and protect the damaged nerve cells. Insulin eyedrops have been shown to be feasible for lowering blood glucose in humans and have been tested for safety and efficacy in animal models.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Diabetes, Retinopathy, Others
52 Participants Needed
Electrical Stimulation for Glaucoma
Palo Alto, California
The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Ocular Herpes Zoster, Uveitis, Pregnancy, Epileptic Seizure, Others
Must Not Be Taking:Acyclovir, Systemic Steroids
30 Participants Needed
Hyperbaric Oxygen Therapy for Optic Neuropathy
Palo Alto, California
The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Corneal Opacification, Pregnancy, Drug Abuse, Others
60 Participants Needed
Electrical Stimulation for Glaucoma
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eyes can help treat open-angle glaucoma. This condition causes eye nerves to die off quickly, and the study aims to see if this new method is safe and effective.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Ocular Herpes Zoster, Retinopathy, Uveitis, Pacemaker, Others
45 Participants Needed
Electrical Stimulation for Glaucoma
Palo Alto, California
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Ocular Herpes Zoster, Nystagmus, Retinopathy, Uveitis, Others
40 Participants Needed
Know someone looking for new options?
Spread the word